SPACE BENEFITS
If the novel bone forming agent proves successful in mitigating bone mass loss in-flight, this
would demonstrate the potential application of pharmacologic sclerostin inhibition as a
countermeasure for use in long-duration human spaceflight missions.
RESULTS
Data is currently under additional analysis.
PUBLICATION(S)
Gridley DS, Mao XW, Tian J, et al. Genetic and apoptotic changes in lungs of mice flown on the
STS-135 mission in space. In Vivo. July 8, 2015;29:423-433.
Hwang S, Crucian BE, Sams CF, Actor JK. Post-spaceflight (STS-135) mouse splenocytes
demonstrate altered activation properties and surface molecule expression. PLOS ONE. May 13,
2015; 10:e0124380. doi: 10.1371/journal.pone.0124380.
Philippou A, Minozzo FC, Spinazzola JM, et al. Masticatory muscles of mouse do not undergo
atrophy in space. FASEB: Federation of American Societies for Experimental Biology Journal.
2015;28(7):2769-2779. doi: 10.1096/fj.14-267336.
Mao XW, Pecaut MJ, Stodieck LS, et al. Biological and metabolic response in STS-135 space-
flown mouse skin. Free Radical Research. August 2014;48:890-897. doi:
10.3109/10715762.2014.920086.
Bailey JF, Hargens AR, Cheng K, Lotz JC. Post-spaceflight recovery of biomechanical properties
of murine intervertebral discs. Gravitational and Space Biology. October 2012;26(2):38-47.
This investigation is complete; however additional results are pending publication.